How do you calculate a nitrosamine limit when there is no carcinogenicity data?
When carcinogenicity data is not available for a nitrosamine impurity, its acceptable intake (AI) limit can be calculated using the Carcinogenic Potency Categorisation Approach (CPCA). This method evaluates the chemical structure and specific molecular features of the impurity to predict its potential carcinogenic potency. Based on the predicted potency category, regulatory authorities such as the US FDA and EMA recommend an appropriate AI limit. Other scientific approaches, including read-across from structurally similar compounds with available toxicity data, may also be considered to establish a justified limit.
For pharmaceutical manufacturers, accurate Nitrosamine Impurity Testing and proper risk assessment are essential to ensure product safety and regulatory compliance. An enhanced Ames test may also help evaluate the mutagenic potential of an impurity and support an alternative acceptable intake limit when justified by regulatory guidance. Professional Nitrosamine Testing Services help identify, quantify, and assess Nitrosamine Impurities in Pharmaceuticals, supporting manufacturers in maintaining product quality and meeting applicable regulatory requirements. Read the full guide: https://www.molkem.com/blog/nitrosamine-acceptable-intake-limits